Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-09-19

Clinical Trial Update: Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial comparing Myrcludex B to Entecavir in HBeAg-negative chronic hepatitis B has completed phases 1 and 2 with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ENTECAVIR (ENTECAVIR)
  • Myrcludex B (bulevirtide)

Snippet

Sponsor: Hepatera Ltd. | Conditions: Chronic Hepatitis B | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-09-19